News

  In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise of Therapeutics from Molecules Within Our Body...

JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer. Dr. Weiss is a physician-scientist and entrepreneur with 25 years of experience in the healthcare and life sciences industries. Dr. Weiss leverages his clinical expertise and business acumen to lead teams...

Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies   Ben Franklin Healthcare Investments continues support of SFA Therapeutics with additional investment. The fund has invested in 4 companies in the southeast Pennsylvania region and continues to be the Philadelphia regions's "Partner with a Purpose" SFA Therapeutics is based in Jenkintown, Montgomery County Pennsylvania   Contacts: INVESTORS Mike Moyer LifeSci Advisors mmoyer@lifesciadvisors.com COMPANY Ira C. Spector, PhD CEO SFA Therapeutics, Inc. iraspector@sfatherapeutics.com   Source: SFA Therapeutics, Inc. Ben Franklin Healthcare Invests $1.3...

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75 $4.5 Million Bridge Financing led by North South Ventures Composition of Matter patent which covers over 40 potential disease indications for SFA-002   JENKINTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, is pleased to announce the completion of a bridge financing of $4.5 million, led...

JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their SFA-002 Phase 1b cohort 1 clinical trial. SFA’s oral pill SFA-002 has the potential to be disease-modifying, with durable responses and an excellent safety profile. SFA-002 simultaneously acts on multiple therapeutic pathways, unlike other drugs on the market which target a single...

Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response to selected infectious agents, mutations, diet, and environmental carcinogens. Homeostasis, which contributes importantly to the definition of “health,” is maintained, in part by the production of short-chain fatty acids (SCFAs), which are metabolites of specific gut bacteria. Alteration in the composition of gut bacteria, or...

Med Tech Gurus Developing The Next Big Thing Ira Spector Co-Founder & CEO of SFA Therapeutics delivers a master class in innovation and new product development. Ira walks us through the best practices of a licensing deal with a university and tell us “don’t be afraid to walk away”. Ira doesn’t stop there, he provides insights into designing elegant experiments and why that is so important in product development. He also...

PODCASTTreat Disease, Not the SymptomsIn this podcast, Dr. Ira Spector discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.Published on: March 7, 2023https://soundcloud.com/act-magazine/treat-disease-not-the-symptoms...

PROFILEA biotech CEO’s favorite ‘F’ wordAt SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.Published Jan. 26, 2023Read Ira Spector's PharmaVoice Profile ...

READ MORE...